---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-24-000039"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:08:21.152818+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spyre reports Q1 net loss $43.9M; cash $485M; SPY001 on track for FIH Q2 2024

## Summary
- Net loss of $43.9M for Q1 2024, including $13.8M non-cash stock comp; vs $18.4M loss in Q1 2023.
- Cash, equivalents, marketable securities, and restricted cash total $485M as of March 31, 2024.
- Raised $180M in March 2024 private placement; expected runway into 2027 through clinical readouts.
- SPY001 (anti-α4β7) cleared 28-day GLP tox; FIH study to start Q2 2024 with interim data expected year-end 2024.
- SPY002 (anti-TL1A) on track for FIH in H2 2024; SPY003 (anti-IL-23 p19) candidate nomination set for mid-2024.

## SEC filing metadata
- accession: 0001636282-24-000039
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/0001636282-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/syre-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-24-000039
- JSON: https://secwatch.observer/filing/0001636282-24-000039.json
- Plain text: https://secwatch.observer/filing/0001636282-24-000039.txt

## Key facts
- Earnings Releases
  Spyre Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: issued a press release announcing its financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/0001636282-24-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.